Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data

Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ramundo V

Authors: Ramundo V, Marciello F, Modica R, Marotta V, Pizza G,

Keywords: Multiple Endocrine Neoplasia type 1, Lanreotide, Duodeno-pancreatic NETs.,

#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors

Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Modica R

Authors: Modica R, Ramundo V, Marciello F, Marotta V, Pizza G,

Keywords: Somatostatin Analogs, Neuroendocrine Tumors,

#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)

Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Marciello F

Authors: Marciello F, Del Prete M, Marotta V, Ramundo V, Buonomano P,

Keywords: prognosis, metformin, RFS, survival,

#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L,

Keywords: somatostatin analogues, MEN1, neuroendocrine tumors, pancreatic neuroendocrine tumor,

#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,